Cargando…

L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma

SIMPLE SUMMARY: Cyclophosphamide exhibits the weakest therapeutic effect compared with vincristine and doxorubicin in the traditional CHOP chemotherapeutic protocol for the treatment of canine lymphoma in previous studies. We want to evaluate the therapeutic effect of a new multi-drug chemotherapy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jih-Jong, Liao, Albert Taiching, Wang, Shang-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388373/
https://www.ncbi.nlm.nih.gov/pubmed/34438662
http://dx.doi.org/10.3390/ani11082199
_version_ 1783742627530670080
author Lee, Jih-Jong
Liao, Albert Taiching
Wang, Shang-Lin
author_facet Lee, Jih-Jong
Liao, Albert Taiching
Wang, Shang-Lin
author_sort Lee, Jih-Jong
collection PubMed
description SIMPLE SUMMARY: Cyclophosphamide exhibits the weakest therapeutic effect compared with vincristine and doxorubicin in the traditional CHOP chemotherapeutic protocol for the treatment of canine lymphoma in previous studies. We want to evaluate the therapeutic effect of a new multi-drug chemotherapy (LHOP) that uses l-asparaginase in place of cyclophosphamide in the traditional CHOP protocol. Twenty dogs with multicentric lymphoma were treated using the LHOP protocol, and the outcomes were historically compared with those of dogs that received CHOP chemotherapy in the same institution. The adverse effects of l-asparaginase were well tolerated and self-limiting. The dogs that received LHOP chemotherapy had a significantly longer progression-free survival than the dogs that received CHOP chemotherapy. Our study findings thus indicate that the LHOP protocol can be used as a first-line chemotherapeutic protocol in canine multicentric lymphoma. ABSTRACT: Cyclophosphamide exhibits the weakest therapeutic effect compared with vincristine and doxorubicin in the CHOP (C, cyclophosphamide; H, doxorubicin; O, vincristine; and P, prednisolone) chemotherapeutic protocol for the treatment of canine lymphoma. Twenty dogs with multicentric lymphoma were treated using the LHOP protocol, which used l-asparaginase in place of cyclophosphamide, and the outcomes were historically compared with those of dogs that received CHOP chemotherapy in the same institution. No significant differences were found in age (p = 0.107), body weight (p = 0.051), sex (p = 0.453), clinical stage V (p = 1), substage b (p = 0.573), T-cell phenotype (p = 0.340), overall response (p = 1), and hypercalcaemia status (p = 1) between the LHOP and CHOP groups. The adverse effects of l-asparaginase were well tolerated and self-limiting. The median PFS (progression-free survival) and median ST (survival time) in the LHOP group were 344 days (range: 28–940 days) and 344 days (range: 70–940 days), respectively. The median PFS and median ST in the CHOP group were 234 days (range: 49–1822 days) and 314 days (range: 50–1822 days), respectively. The dogs that received LHOP chemotherapy had a significantly longer PFS than the dogs that received CHOP chemotherapy (p = 0.001). No significant difference was observed in ST between the LHOP and CHOP groups (p = 0.131). Our study findings thus indicate that the LHOP protocol can be used as a first-line chemotherapeutic protocol in canine multicentric lymphoma.
format Online
Article
Text
id pubmed-8388373
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83883732021-08-27 L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma Lee, Jih-Jong Liao, Albert Taiching Wang, Shang-Lin Animals (Basel) Article SIMPLE SUMMARY: Cyclophosphamide exhibits the weakest therapeutic effect compared with vincristine and doxorubicin in the traditional CHOP chemotherapeutic protocol for the treatment of canine lymphoma in previous studies. We want to evaluate the therapeutic effect of a new multi-drug chemotherapy (LHOP) that uses l-asparaginase in place of cyclophosphamide in the traditional CHOP protocol. Twenty dogs with multicentric lymphoma were treated using the LHOP protocol, and the outcomes were historically compared with those of dogs that received CHOP chemotherapy in the same institution. The adverse effects of l-asparaginase were well tolerated and self-limiting. The dogs that received LHOP chemotherapy had a significantly longer progression-free survival than the dogs that received CHOP chemotherapy. Our study findings thus indicate that the LHOP protocol can be used as a first-line chemotherapeutic protocol in canine multicentric lymphoma. ABSTRACT: Cyclophosphamide exhibits the weakest therapeutic effect compared with vincristine and doxorubicin in the CHOP (C, cyclophosphamide; H, doxorubicin; O, vincristine; and P, prednisolone) chemotherapeutic protocol for the treatment of canine lymphoma. Twenty dogs with multicentric lymphoma were treated using the LHOP protocol, which used l-asparaginase in place of cyclophosphamide, and the outcomes were historically compared with those of dogs that received CHOP chemotherapy in the same institution. No significant differences were found in age (p = 0.107), body weight (p = 0.051), sex (p = 0.453), clinical stage V (p = 1), substage b (p = 0.573), T-cell phenotype (p = 0.340), overall response (p = 1), and hypercalcaemia status (p = 1) between the LHOP and CHOP groups. The adverse effects of l-asparaginase were well tolerated and self-limiting. The median PFS (progression-free survival) and median ST (survival time) in the LHOP group were 344 days (range: 28–940 days) and 344 days (range: 70–940 days), respectively. The median PFS and median ST in the CHOP group were 234 days (range: 49–1822 days) and 314 days (range: 50–1822 days), respectively. The dogs that received LHOP chemotherapy had a significantly longer PFS than the dogs that received CHOP chemotherapy (p = 0.001). No significant difference was observed in ST between the LHOP and CHOP groups (p = 0.131). Our study findings thus indicate that the LHOP protocol can be used as a first-line chemotherapeutic protocol in canine multicentric lymphoma. MDPI 2021-07-26 /pmc/articles/PMC8388373/ /pubmed/34438662 http://dx.doi.org/10.3390/ani11082199 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Jih-Jong
Liao, Albert Taiching
Wang, Shang-Lin
L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma
title L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma
title_full L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma
title_fullStr L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma
title_full_unstemmed L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma
title_short L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma
title_sort l-asparaginase, doxorubicin, vincristine, and prednisolone (lhop) chemotherapy as a first-line treatment for dogs with multicentric lymphoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388373/
https://www.ncbi.nlm.nih.gov/pubmed/34438662
http://dx.doi.org/10.3390/ani11082199
work_keys_str_mv AT leejihjong lasparaginasedoxorubicinvincristineandprednisolonelhopchemotherapyasafirstlinetreatmentfordogswithmulticentriclymphoma
AT liaoalberttaiching lasparaginasedoxorubicinvincristineandprednisolonelhopchemotherapyasafirstlinetreatmentfordogswithmulticentriclymphoma
AT wangshanglin lasparaginasedoxorubicinvincristineandprednisolonelhopchemotherapyasafirstlinetreatmentfordogswithmulticentriclymphoma